Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for Achondroplasia - Nasdaq https://t.co/vsgUlfjH0q
— Discovery Institute (@discoverynj) March 1, 2019
from Twitter https://twitter.com/discoverynj
February 28, 2019 at 10:09PM
No comments:
Post a Comment